Nanobiotix S.A. – Sponsored ADR (NBTX) – What Are Analysts Thinking About This Stock?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $46.67.

NBTX has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, October 15th. Guggenheim began coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock.

Nanobiotix Trading Up 13.0%

Shares of Nanobiotix stock opened at $29.19 on Friday. The firm’s 50-day simple moving average is $33.62 and its 200-day simple moving average is $36.47. Nanobiotix has a twelve month low of $14.78 and a twelve month high of $57.14.

Nanobiotix Company Profile

Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.

Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.